The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use,
The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of Aicuris for approximately €780m ($920.7m) earlier this year. The acquisition aligns with Asahi Kasei’s
The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. Subject to customary conditions and anti-trust clearance, the transaction is
This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. Enflonsia is a long-acting monoclonal antibody intended for prevention, providing protection over
This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by
The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities. Interna’s MNM molecules
The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data,
This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with
The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main
The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. The therapy is anticipated to have a US Food and Drug Administration
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.